Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Ocular surface disease associated with dupilumab treatment for atopic diseases.

Tytuł:
Ocular surface disease associated with dupilumab treatment for atopic diseases.
Autorzy:
Utine CA; Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey; Izmir Biomedicine and Genome Center, Izmir, Turkey.
Li G; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Asbell P; The Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Pflugfelder S; Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.
Akpek E; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .
Źródło:
The ocular surface [Ocul Surf] 2021 Jan; Vol. 19, pp. 151-156. Date of Electronic Publication: 2020 May 18.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Publication: 2012- : [Philadelphia, PA] : Elsevier Inc.
Original Publication: New York, N.Y. : Ethis Communications, [c2003]-
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Dermatitis, Atopic*/drug therapy
Antibodies, Monoclonal ; Humans ; Interleukin-13
Contributed Indexing:
Keywords: Atopic dermatitis; Conjunctivitis; Dupilumab
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Interleukin-13)
420K487FSG (dupilumab)
Entry Date(s):
Date Created: 20200523 Date Completed: 20210624 Latest Revision: 20210624
Update Code:
20240105
DOI:
10.1016/j.jtos.2020.05.008
PMID:
32439390
Czasopismo naukowe
Dupilumab is the first US FDA approved biologic for treatment of atopic dermatitis. It is a human monoclonal antibody which blocks the shared receptor component, the interleukin (IL)-4α subunit, of IL-4 and IL-13 signaling pathways. Occurrence of "conjunctivitis", mostly in atopic dermatitis trials, has been the main side effect reported thus far. The etiology of "conjunctivitis" associated with dupilumab treatment is unclear and might be similar to atopic keratoconjunctivitis. There is evidence in the published literature that unlike the Th2-like profile in vernal keratoconjunctivitis, Th1-mediated inflammation is predominant in atopic keratoconjunctivitis. Blocking the Th2 pathway with dupilumab therapy might result in a shift towards Th1, causing the ocular findings associated with dupilumab. In addition, blockage of IL-13 might have implications with regards to mucin production and ocular surface health. This review highlights the clinical manifestations, reviews treatment options and offers explanations for pathogenesis of this ocular surface diseases associated with dupilumab treatment.
(Copyright © 2020 Elsevier Inc. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies